

**REGISTER BEFORE APRIL 12
& SAVE UP TO \$500**

June 24-26, 2019 | Boston, MA
www.giid-summit.com



GIIDS

GI Inflammatory Diseases Summit

Developing More Clinically Safe & Efficacious Therapeutics for GI Inflammatory Diseases

Your 24 expert speakers, including:



**Andres
Hurtado-Lorenzo**
Senior Director,
Translational
Research
**Crohn's & Colitis
Foundation**



Meina Tang
Principal Scientist,
Clinical Pharmacology
Genentech



Carolyn Cuff
Senior Director,
Translational
Immunology
Department
AbbVie



Peter Bunyard
Head, Immunology
Biology
RedX Pharma



Arpita Maiti
Senior Director, External
Science, Innovation,
Inflammation,
Immunology &
Microbiome
Pfizer

Welcome to GIIDS

Delivering higher rates of clinical remission, demonstrating more gut-selective pharmacology and minimizing adverse side effects of your IBD candidate

Developed in combination with 20 stakeholders including **AbbVie**, **Theravance** and **Genentech**: GIIDS will be the first end-to-end drug development forum focused exclusively on delivering more clinically safe and efficacious treatments for patients suffering from chronic GI inflammation.

Across 3 days of in-depth discussion, share perspectives with industry leaders and **overcome translational drug development challenges** including: clinical trial design in a hyper-competitive landscape, targeting alternative pro-inflammatory pathways, and the potential of emerging antigen-specific and bio-therapeutics.

Be part of this inaugural summit to collaborate and gain the knowledge you need to **confidently navigate the next 12 months of your anti-inflammatory and IBD research**.

Hear what previous Hanson Wade event attendees have to say

Thought this disease specific conference was informative, by planning a concentrated topic it gave an opportunity to look through a tighter lens

Genentech

The conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics

AstraZeneca

This is my 3rd Hanson Wade conference and I have left each time very satisfied having considerably improved my knowledge base and meeting some serious experts in the field

Daichii Sankyo

Top 5 Reasons to Attend GIIDS:

1.

Clarifying Clinical Trial Design with Genentech

Reinforce your awareness on significant considerations for clinical trials such as designing paediatric studies, defining histological endpoints and designing adaptive clinical trials to ensure better execution of your trials

2.

Manipulating the Microbiome & Emerging Biotherapeutics with BiomX

Understand the influence of the host-microbiome interactions with IBD pathogenesis to better contextualize the potential of microbial derived therapeutics

3.

Bettering Biomarkers with Abbvie

Hear translational insights on markers of mucosal healing, pharmacogenomics in ulcerative colitis and successful pharmacodynamic biomarkers to assist and streamline your own drug development

4.


Safer Small Molecules with Immunic

Analyze case studies of novel small molecule candidates targeting IBD and related fibrosis to better achieve intestinal inflammation remission

5.

Insights Outside of IBD with Innovate Biopharmaceuticals

Leverage insights and lessons learned from drug development in wider pathological inflammation to maximize your understanding of this landscape and the anti-inflammatory arsenal already in play



Your 24 Expert Speakers



Adam Cheifetz
Director, Center of
Inflammatory Bowel
Disease
**Beth Israel Deaconess
Medical Center**



Alan Moss
Associate Professor of
Medicine
**Harvard Medical
School**



Alexis Scherl
Scientist, Research
Pathologist
Genentech



**Andres Hurtado-
Lorenzo**
Senior Director,
Translational Research
**Crohn's & Colitis
Foundation**



Arpita Maiti
Senior Director, External
Science, Innovation,
Inflammation,
Immunology &
Microbiome
Pfizer



Assaf Oron
Chief Business Officer
BiomX



Ben Bradley
Head, Partnerships &
Licensing
Chain Biotech



Carolyn Cuff
Senior Director,
Translational
Immunology
Department
AbbVie



Christine McDonald
Associate Staff, Lerner
Research Institute
Cleveland Clinic



Diane Peters
Postdoctoral Fellow
**John Hopkins Drug
Discovery**



Elran Haber
Chief Executive Officer
Biomica



Fotini Gounari
Associate Professor,
Department of
Medicine
**The University of
Chicago**



Hella Kohlhof
Chief Scientific Officer
Immunix Therapeutics



Jason Ridlon
Assistant Professor
**University of Illinois
at Urbana Champaign**



Jay Madan
Founder, President &
Chief Business Officer
**Innovate
Biopharmaceuticals**



Jennifer Wortman
Vice President, Clinical
Discovery & Research
Technologies
Seres Therapeutics



Khashayarsha Khazie
Professor, Immunology
Mayo Clinic



Meina Tang
Principal Scientist,
Clinical Pharmacology
Genentech



Mina Hassan-Zahraee
Director, Precision
Medicine, Early Clinical
R&D
Pfizer



Pernilla Sandwall
Chief Operating Officer
**InDex
Pharmaceuticals**



Peter Bunyard
Head, Immunology
Biology
RedX Pharma



Rex Gaskins
Professor
**University of Illinois
at Urbana Champaign**



Rob Yang
Computational Biology
Group Leader, I&I TCoE
Celgene



Sara Tezza
Principal Scientist
AnTolRx

Conference Day One

Monday June 24 2019

	8.00 Registration & Welcome
	8.20 Chair's Opening Remarks
Designing & Executing Clinical Trials in a Hypercompetitive Market	
Andres Hurtado-Lorenzo Senior Director, Translational Research Crohn's & Colitis Foundation	8.30 Keynote: Advancing Precision Medicine in IBD to Deliver Tailored Treatments - Highlighting the efforts of the Crohn's & Colitis Foundation to advance precision medicine, including the identification and validation of predictive and prognostic biomarkers - Integrating deep molecular and clinical phenotyping to improve disease prognosis and treatment response predictions
Meina Tang Principal Scientist, Clinical Pharmacology Genentech	9.00 Designing Pediatric Studies Towards More Executable Trials for Pediatric IBD Patients - Accelerating pediatric development timelines using a partial extrapolation approach as outlined by the FDA - Maximally leveraging available data (including RWD) when designing pediatric phase III study: considerations in the selection of appropriate dose, sample size, control, and study duration
	9.30 Speed Networking This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the IBD and anti-inflammatory drug development and establish meaningful business relationships.
	10.15 Morning Break
Mina Hassan-Zahraee Director, Precision Medicine, Early Clinical R&D Pfizer	11.00 Molecular Profiling of Ulcerative Colitis & Crohn's Patients - Presenting novel pharmacodynamic and clinical efficacy biomarkers uncovered by the TURANDOT and OPERA trials - Discussing a mechanistic rationale for a non-monotonic dose response
Pernilla Sandwall Chief Operating Officer InDex Pharmaceuticals	11.30 Clinical Development of the TLR-9 Agonist Cobitolimod for Ulcerative Colitis Patients: A Late Stage Drug Candidate with a Novel Mode of Action - Discussing cobitolimod as a potential new medication for moderate to severe ulcerative colitis with a novel and unique mechanism of action - Sharing compelling efficacy and excellent safety profile of cobitolimod in previous clinical studies - Discussing ongoing phase IIb dose optimisation study with cobitolimod with results expected H1 2019
Alexis Scherl Scientist, Research Pathologist Genentech	12.00 Implementing Histologic Endpoints in IBD Clinical Trials - Overview of IBD Histology - Choosing and implementing a histopathology index - Defining histologic endpoints
	12.30 Lunch & Networking

Patient Profiling & Mucosal Markers: Translational Lessons to Optimize Drug Development

Rob Yang Computational Biology Group Leader, I&I TCoE Celgene	1.30 Pharmacogenomics in Ulcerative Colitis - Analyzing UC patients as heterogeneous by molecular signatures - Profiling human cohorts and clinical trial cohorts can shed lights to disease stratification and respective responses to therapy - Discussing why end points matter
Carolyn Cuff Senior Director, Translational Immunology Department AbbVie	2.00 Achieving Mucosal Healing as a Target for Therapeutic Efficacy in IBD - More precisely defining mucosal healing as an endpoint for regulators and patients - Approaches taken by the field to identify markers of mucosal healing - Potential Future State
	2.30 Afternoon Break & Networking

Reducing Toxicity with the Next Generation of Small Molecules

Hella Kohlhof Chief Scientific Officer Immunix Therapeutics	3.30 IMU-838 in Clinical Phase 2 - New Selective Oral Treatment for IBD - Presenting first in class in IBD - Demonstrating selectivity by targeting immune metabolism
Diane Peters Postdoctoral Fellow John Hopkins Drug Discovery	4.00 FOLH1/GCPII Inhibitors: Novel Small Molecule Therapeutics for the Treatment of IBD - Glutamate carboxypeptidase (GCP) is highly overexpressed in both Crohn's disease and ulcerative colitis - Demonstrating robust anti-IBD efficacy of GCP inhibitors in murine colitis models when administered systemically and orally - Presenting inhibition of GCP as a novel therapeutic strategy for IBD management
Peter Bunyard Head, Immunology Biology RedX Pharma	4.30 GI-Targeted ROCK for Crohn's Disease-Related Fibrosis - Demonstrating ROCK as an attractive target for treating fibrosis, but hypotension risks limit development of small molecule inhibitors for systemic application - Sharing a series of compounds developed by Redx that target ROCK exclusively in the GI track through intestinal retention and plasma instability - Highlighting Redx's GI targeted ROCK inhibitors as highly potent, selective and able to reverse established fibrosis in murine models of intestinal tissue remodelling
	5.00 Chair's Closing Remarks
	5.10 Scientific Poster Session: The Poster Session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships.

“ This meeting gathered all experts in the field to share ideas and data. It was quite an eye opener. I feel I came home with excitement and a brand new mind towards my work in the field ”

Pfizer

Conference Day Two

Tuesday June 25 2019

	8.20 Chair's Opening Remarks
Arpita Maiti Senior Director, External Science, Innovation, Inflammation, Immunology & Microbiome Pfizer	8.30 Evaluating Early Stage Challenges & Opportunity for Partnerships in IBD - Focusing on biology and strategies to overcome early stage challenges limiting IBD drug development - Sharing partnering models to access and accelerate promising innovations
Adam Cheifetz Director, Center of Inflammatory Bowel Disease Beth Israel Deaconess Medical Center	9.00 Role of Therapeutic Drug Monitoring in IBD - Describing the role of therapeutic drug concentration monitoring (TDM) with biologics - Discussing reactive versus proactive TDM - Learning potential benefits of proactive TDM in the treatment of IBD

Keeping it in The Colon: Targeted Pharmacology in the Gut

Sara Tezza Principal Scientist AnToIRx	9.30 Antigen-Specific Biologics for The Treatment of IBD - Introducing and contextualizing Aryl Hydrocarbon Receptor (AhR) signaling in autoimmunity and a customizable nanoliposome platform for the re-establishment of antigen-specific tolerance - Presenting AhR signaling in the control of gut inflammation and perspectives for translation into patients
--	---

10.00 Mastermind Discussions

This session facilitates in-depth discussions among participants in an informal environment. After splitting into groups, participants will discuss key issues and challenges regarding the current landscape of anti-inflammatory, gut-selective drug development.

Better Recapitulating Human IBD to More Robustly Translate into The Clinic

- Strategies to Overcome Shortfalls of Existing Preclinical Models
- Pitfalls & Utility of Genetically Modified Mouse Phenotypes
- Potential Use of Human Stem-Cell Derived Intestinal Organoids to Study IBD *in Vitro*

Will we Achieve a Better Class of Candidates?

- Oral Gut Selective Vs Systemic JAK Inhibitors
- Anti-Integrin as a new frontline for IBD
- Comparative Effectiveness of Old & New Biologics

10.30 Morning Break & Networking

Manipulating the Microbiome: Harnessing the Immune System Microbiota Paradigm

Christine McDonald Associate Staff, Lerner Research Institute Cleveland Clinic	11.30 The Immune System & the Microbiome: Drivers of IBD Pathogenesis & Opportunities for IBD Therapeutics - Innate immune system modulators as IBD therapeutics - Highlighting NOD2 targeting strategy as an effective treatment for IBD - Detailing the influence of diet on host-microbiome interaction and IBD pathogenesis
--	--

Alan Moss Associate Professor of Medicine Harvard Medical School	12.00 Positioning Microbial Therapies in the IBD Treatment Algorithm • Presenting and comparing current treatment paradigms • Evidencing a microbial role in IBD • Validating microbial therapy in induction & remission of IBD inflammation
Jennifer Wortman Vice President, Clinical Discovery & Research Technologies Seres Therapeutics	12.30 Safety & Efficacy of an Investigational Oral Microbiome Therapeutics for the Treatment of IBD • Outlining development and phase 1b results of SER-287 in patients with UC
	1.00 Lunch & Networking
Elran Haber Chief Executive Officer Biomica	2.00 Microbiome Functional Genomics Reveals Novel Bacterial Strains for Reduction of Inflammation in Crohn's Disease • The intestinal microbiome has been implicated in the pathogenesis of inflammatory bowel disease • Using a novel high-resolution computational predictive biology platform enables the identification of microbial-derived functions relevant to inflammatory disease activity, and microbial strains bearing specific inflammation-reduction activity
Ben Bradley Head, Partnerships & Licensing Chain Biotech	2.30 Targeted Biotherapeutics for Ulcerative Colitis Using Engineered Anaerobic Bacteria • CHAIN are developing novel live biotherapeutics based on a single selected clostridium species. The microbe is engineered to produce a specific therapeutic payload and the clinical focus is gut microbiome related inflammatory and infectious diseases • Introducing platform technology and a summary of CHN1 progress, an engineered clostridium strain in pre-clinical development for ulcerative colitis
	3.00 Afternoon Break & Networking
Assaf Oron Chief Business Officer BiomX	3.30 Hitting Bacterial Targets for IBD With Phage Therapeutics • Outlining pro-inflammatory bacterial targets linked to the onset and aggravation of IBD • Presenting BX002 a customized phage cocktail aimed at these bacterial targets
Jay Madan Founder, President & Chief Business Officer Innovate Biopharmaceuticals	4.00 Insights Outside of IBD to Inform New Therapeutic Targets • Discussing renormalization of intestinal permeability in Celiac Disease • Evaluating other diseases where intestinal barrier restoration can help
	4.30 Chair's Closing Remarks

■ I like Hanson Wade's way of putting together smaller, but more specific meetings. It's definitely my favorite and I'm coming back next year ■

EMD Serono

Post-Conference Workshop

Wednesday June 26 2019

Workshop

9.00am - 12.00pm

Regulation of Colon Inflammation by Regulatory T-Cells, Microbiota & Bile Acid Metabolism

Bacterial metabolism of bile acids is mechanistically linked to genotoxic and inflammatory process that predispose to IBD and colorectal cancer (CRC). Bile acid metabolizing bacteria are also responsible for the extrathymic generation of regulatory T-cells, the rate limiting factors in the control of colon inflammation. Deregulation of inflammation involves epigenetic and gene expression changes that take place in gut infiltrating regulating T-cells.

Understanding the interface of gut microbiota and Treg function in the gut will critically help in designing effective preventive and therapeutic strategies.

Join these experts as they present in detail on:

- Treg diversity and function in colon cancer
- Molecular pathways that regulate Treg functions and Treg/Th17 balance
- Microbial sulfur metabolism and colorectal cancer risk
- Genetics of bile acid metabolism and colorectal cancer risk

Workshop Leaders



Khashayarsha Khazaei
Professor of Immunology
Mayo Clinic

Khashayarsha Khazaie, Ph.D., D.Sc., directs basic and translational research in cancer

immunology and immunosenescence.

Dr. Khazaie's lab studies immune responses that help tumors grow and spread as well as immune responses that protect against cancer. A major focus is on regulatory T cells (Tregs), their subsets, and their diverse functions in regulating inflammation and immunity in the gastrointestinal tract. In this context, there is interest in the role of microbiota and circadian rhythm.



Rex Gaskins
Professor
University of Illinois at Urbana Champaign

Rex Gaskins' laboratory focuses on host-intestinal microbe interactions relevant to

colorectal cancer with a particular interest in microbial sulfur and hydrogen metabolism. Efforts to understand colonic mucosal responses to hydrogen sulfide led to further interest in redox regulation of tumorigenesis resulting in a long-time collaboration with bioengineering faculty at Illinois to create genetically-encoded biosensors and engineered platforms for the study of redox poise in subcellular compartments in live cells.

Professor Gaskins has authored 156 peer-reviewed publications and book chapters and has won numerous awards including a Future Leaders Award from the International Life Sciences Institute, the Bio-Serv Award from the American Society of Nutrition, a Burroughs Wellcome Fund visiting scientist fellowship (University of Reading), and a Sir Frederick McMaster CSIRO Research Fellowship (University of Queensland).



Fotini Gounari
Associate Professor,
Department of Medicine
The University of Chicago

Dr. Fotini Gounari Ph.D. is a molecular immunologist and an expert in thymic development and mucosal immunity.

Her areas of research are T-cell/regulatory T-cell development and function. Her studies focus on the Wnt/b-catenin signaling in T-lymphocytes and the interface of this pathway with gut microbiota and their metabolites. Dr. Gounari aims to identify key molecular pathways that are deregulated in chronic inflammation and cancer. Identification of such pathways will elucidate the molecular etiology of autoimmune diseases and cancer, and holds the promise to lead to effective immune therapies.



Jason Ridlon
Assistant Professor
University of Illinois at Urbana Champaign

Jason Ridlon's laboratory focuses on the human gut "sterolbiome", the collective genes

involved in biotransformation of bile acids, glucocorticoids, and pharmaceutical steroids.

His laboratory studies sterolbiome genes and enzymes in several model systems including germ-free mice and chickens, mini-bioreactors, and human clinical samples. His lab utilizes transcriptomics, metagenomics, enzymology and structural biology to study the sterolbiome at multiple levels with the goal to modulate the steroid and bile acid metabolome and generate specific inhibitors of sterolbiome targets to accomplish this, with the long-term goal of treating human disease and improving animal production.

Partnership Opportunities

Why Partner with GIIDS?

GIIDS is your fastest route to organizations prioritizing IBD drug development.

Gathering stakeholders with preclinical and clinical candidates, this will be your opportunity to showcase your brand, your message, your reputation to 60+ drug developers from organizations across gastroenterology, immunity and inflammation. This is your opportunity to elevate your company's standing and influence in this rapidly advancing field.


Showcase your innovations at GIIDS to **build new connections, further cement partnerships,**

and **demonstrate why you are the first choice service provider** to drug developers.

We understand each business is different so we'll work with you to build a bespoke package to fulfil your 2019/2020 business objectives. Whether that is presenting on the agenda, hosting networking sessions, exhibiting, or brand exposure, we have opportunities that offer it all.


Contact us today to find out more
sponsor@hansonwade.com

Attending companies:



Large & Medium Pharma
Biotech
Academia
Clinical CROs
Preclinical Modelling Companies & CROs
Diagnostic Companies

Attending Seniority:



C-Level: 23%
Vice President: 16%
Senior Director / Director: 29%
Project Team/ Program Leader: 12%
Principal Scientist/ Scientist: 12%
Professor: 8%

*Based on market research and previous events' statistics

Great event exceptional networking opportunities. High quality of presentations. Very efficient way to spend my time

Synexus

Become a Partner



Jakub Nunuk
Partnerships Manager
Tel: : +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

 www.giid-summit.com/register

 Tel: +1617 455 4188

 Email: info@hansonwade.com

- 1 Understand the pharmacology, safety and efficacy of emerging candidates to treat chronic inflammatory diseases
- 2 Gain valuable new and strengthened connections with key thought leaders and decision makers
- 3 Participate in uniquely focussed discussions to analyse all aspects of IBD drug development with your peers, through a tighter lens

Team Discounts*

- 10% discount – 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Contact: register@hansonwade.com

Secure Your Place

	Register & Pay By Friday, April 12	Standard Prices
Conference + 1 Workshop	\$2998 (save \$500)	\$3498 (save \$100)
Conference Only	\$2499 (save \$400)	\$2899
Workshops Only	\$699	

***Academics are entitled to a 40% discount off the Industry Pricing**

(Please note discounts cannot be combined with any other offer)



Venue

The Revere Boston Common
Revere Hotel Boston, 200 Stuart Street
Boston, Massachusetts, 02116

For further information or assistance, please visit
www.reverehotel.com/

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Code: 8149